CAS 134381-21-8

Epoxomicina

Descripción:

Epoxomicina es un potente e inhibidor selectivo del proteasoma, conocido principalmente por su papel en la investigación relacionada con el cáncer y las enfermedades neurodegenerativas. Es un producto natural derivado de la fermentación de la bacteria *Streptomyces*. El compuesto presenta un grupo funcional epóxido único, que contribuye a su mecanismo de acción al unirse covalentemente al sitio activo del proteasoma, inhibiendo así su función. Esta inhibición conduce a la acumulación de proteínas reguladoras y apoptosis en células cancerosas, lo que lo convierte en una herramienta valiosa en la investigación del cáncer. Epoxomicina también se ha estudiado por sus posibles efectos neuroprotectores, ya que puede influir en la degradación de proteínas mal plegadas asociadas con trastornos neurodegenerativos. En términos de propiedades físicas, Epoxomicina se caracteriza típicamente por su estado sólido a temperatura ambiente y es soluble en disolventes orgánicos. Su uso en entornos de laboratorio requiere un manejo cuidadoso debido a su actividad biológica y potencial toxicidad. En general, Epoxomicina sirve como un compuesto importante en el estudio de la función del proteasoma y sus implicaciones en varias enfermedades.

Fórmula: C₂₈H₅₀N₄O₇

InChI: InChI=1/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-26(37)22(18(7)33)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,29,33H,11-14H2,1-10H3,(H,30,38)(H,31,36,37)/t16-,17-,18+,20?,21-,22-,23-,28+/m0/s1

Clave InChI: InChIKey=DOGIDQKFVLKMLQ-JTHVHQAWSA-N

SMILES: C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N(C(C)=O)C)[C@H](CC)C)=O)[C@H](CC)C)=O)[C@@H](C)O)=O)CC(C)C)(=O)[C@@]1(C)CO1

Sinónimos:

• (2R)-2-[Acetyl-(N-Methyl-L-Isoleucyl)-L-Isoleucyl-L-Threonyl-L-Leucyl]-2-Methyloxirane
• <span class="text-smallcaps">L</smallcap>-Threoninamide, N-acetyl-N-methyl-<smallcap>L</smallcap>-isoleucyl-<smallcap>L</span>-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-
• <span class="text-smallcaps">L</smallcap>-Threoninamide, N-acetyl-N-methyl-<smallcap>L</smallcap>-isoleucyl-<smallcap>L</span>-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-
• Bu-4061T
• Epoxomicin, Synthetic
• N-Acetyl-N-Methyl-L-Isoleucyl-L-Isoleucyl-N-[(1S)-3-Methyl-1-[[(2R)-2-Methyloxiranyl]Carbonyl]Butyl]-L-Threoninamide
• N-Acetyl-N-methyl-<span class="text-smallcaps">L</smallcap>-isoleucyl-<smallcap>L</smallcap>-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-<smallcap>L</span>-threoninamide
• N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-L-threonyl-N-{2-[(2R)-2-methyloxiran-2-yl]-2-oxoethyl}-L-leucinamide
• N-acetyl-N-methyl-L-isoleucyl-N-{(2S,3R)-3-hydroxy-2-[(3-methyl-1-{[(2R)-2-methyloxiran-2-yl]carbonyl}butyl)amino]butanoyl}-L-isoleucinamide
• N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-threoninamide
• L-Threoninamide, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-
• L-Threoninamide, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-
• Epoxomicin
• Epoxomicin(BU-4061T)
• Aids010837
• CS-1626
• Aids-010837
• Epoxomicin, 97%, a selective proteasome inhibitor
• BU-4061T,Aids010837
• (2S,3S)-2-[[(2S,3S)-2-[acetyl(Methyl)aMino]-3-Methylpentanoyl]aMino]-N-[(2S,3R)-3-hydroxy-2-[[(2S)-4-Methyl-1-[(2R)-2-Methyloxiran-2-yl]-1-oxopentan-2-yl]aMino]butanoyl]-3-MethylpentanaMide
• EPOXOMICIN;BU4061T;BU-4061T
• 134381-21-8 supplier in China

Epoxomicin

CAS: 134381-21-8

Fórmula: C₂₈H₅₀N₄O₇

Pureza: 95%

Forma y color: Solid

Peso molecular: 554.7192

Ref: IN-DA007MB6

Epoxomicin

CAS: 134381-21-8

Epoxomicin

Pureza: ≥98%

Peso molecular: 554.72g/mol

Ref: 54-BUP08315

Epoxomicin

CAS: 134381-21-8

Fórmula: C₂₈H₅₀N₄O₇

Pureza: ≥ 98.0%

Forma y color: White to off-white or light-yellow solid

Peso molecular: 554.7

Ref: 7W-GL3424

Epoxomicin

CAS: 134381-21-8

Epoxomicin, a selective proteasome inhibitor, chiefly blocks CH-L activity, mildly affecting T-L and PGPH at lower rates.

Fórmula: C₂₈H₅₀N₄O₇

Pureza: 98.65% - 98.86%

Forma y color: White To Off-White Solid

Peso molecular: 554.72

Ref: TM-T6830

Epoxomicin

CAS: 134381-21-8

Epoxomicin is an activator that binds to the ligand-binding site of a receptor. It has been used as a research tool in cell biology, pharmacology, and immunology. Epoxomicin has been shown to inhibit ion channels by binding to them and blocking their activity. This property makes epoxomicin a good candidate for the treatment of epilepsy. Epoxomicin also inhibits protein synthesis through inhibition of ribosomal S6 kinase, which is involved in signal transduction pathways.

Fórmula: C₂₈H₅₀N₄O₇

Pureza: Min. 95%

Peso molecular: 554.72 g/mol

Ref: 3D-IEP-4381-V

Epoxomicin

CAS: 134381-21-8

Epoxomicin is a macrolide antibiotic that inhibits the production of inflammatory mediators by suppressing the activity of protein kinase C. Epoxomicin has been shown to have anti-inflammatory properties in low doses. This drug also inhibits the proteasome, an enzyme that breaks down proteins into amino acids or small peptides, and is used as an inhibitor of cancer cell proliferation. Epoxomicin binds to the 20S proteasome at a site that is distinct from that for other proteasome inhibitors such as lactacystin and bortezomib, which are used for cancer treatment. The binding site for epoxomicin is adjacent to the ATP-binding site and may be due to its inhibitory effect on ATP hydrolysis.

Fórmula: C₂₈H₅₀N₄O₇

Pureza: Min. 95%

Forma y color: Powder

Peso molecular: 554.72 g/mol

Ref: 3D-JFA38121